Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Accumulated Depreciation & Amortization (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Accumulated Depreciation & Amortization over the past 10 years, most recently at $3.6 million for Q4 2023.

  • For Q4 2023, Accumulated Depreciation & Amortization rose 14.96% year-over-year to $3.6 million; the TTM value through Dec 2023 reached $3.6 million, up 14.96%, while the annual FY2023 figure was $3.6 million, 14.96% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2023 was $3.6 million at Corbus Pharmaceuticals Holdings, up from $3.4 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3.6 million in Q4 2023 and troughed at $819205.0 in Q1 2019.
  • A 5-year average of $2.4 million and a median of $2.6 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 221.83% in 2019 and later decreased 4.99% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.4 million in 2019, then soared by 67.06% to $2.3 million in 2020, then increased by 1.0% to $2.4 million in 2021, then surged by 30.39% to $3.1 million in 2022, then grew by 14.96% to $3.6 million in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for CRBP at $3.6 million in Q4 2023, $3.4 million in Q3 2023, and $3.3 million in Q2 2023.